Replimune Group stock (US76029N1063): shares jump after FDA resubmission path for melanoma therapy

Replimune Group shares on Nasdaq rallied after the United States biotech company said it had reached an agreement with the FDA on a path to resubmit its biologics license application for RP1 in advanced melanoma, reviving a program that faced earlier setbacks.

Replimune Group shares gained sharply on the Nasdaq after the United States oncology biotech announced it has reached an agreement with the U.S. Food and Drug Administration on a path to resubmit a biologics license application for its lead oncolytic immunotherapy RP1 in combination with nivolumab for advanced melanoma, according to a news report summarizing the company’s statement as of 06/02/2026.Stocktwits News as of 05/29/2026

The agreement with the FDA follows previous rejections of the RP1 application and provides a route for the Massachusetts-based company, whose stock trades on Nasdaq under the ticker REPL, to move forward with its melanoma program in the United States market, a key home-country regulatory milestone highlighted in industry coverage of the announcement.Albert Vilella Substack as of 06/02/2026

The stock reaction to the FDA resubmission path was pronounced, with one market commentary noting that Replimune shares surged as much as about 80 percent at market open on the session following the disclosure, as investors reassessed the prospects for the RP1 melanoma indication in light of the renewed regulatory dialogue in the United States.Stocktwits News as of 05/29/2026

As of the latest close referenced in public trading data, Replimune Group shares changed hands at USD 9.00 on Nasdaq on 06/02/2026, compared with USD 9.72 at the start of 2026, implying a decline of about 7.4 percent year-to-date even after the recent volatility around the FDA news, according to market statistics compiled by a stock analysis platform.MarketBeat as of 06/02/2026

The stock traded at USD 9.00 on 06/02/2026 on Nasdaq, according to MarketBeat as of 06/02/2026.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Replimune Group
• Sector/industry: Biotechnology - oncolytic immunotherapies
• Headquarters/country: Woburn, United States
• Core markets: United States, Europe
• Key revenue drivers: Development of oncolytic immunotherapy candidates such as RP1 and related pipeline assets for cancer indications
• Home exchange/listing venue: Nasdaq (REPL)
• Trading currency: USD

Replimune Group: core business model

Replimune Group focuses on developing oncolytic immunotherapies that are designed to stimulate the immune system to attack tumors, with value creation tied primarily to advancing its clinical-stage assets like RP1 and related candidates toward potential approvals and commercialization.

Latest quarterly results for Replimune Group at a glance

For its third quarter of fiscal 2026, reported on 02/03/2026, Replimune Group posted a net loss per share of USD -0.77, which was narrower than the consensus analyst estimate of USD -0.85 by USD 0.08, according to an earnings summary that cites the company’s filings.MarketBeat earnings overview as of 02/03/2026

The same source indicates that Replimune’s next earnings publication is estimated for 07/30/2026, based on the timing of prior reports, which keeps upcoming financial updates on the calendar for investors following the company’s cash burn profile and clinical development spending in the United States and other core markets.MarketBeat earnings overview as of 02/03/2026

Conclusion

The disclosed agreement with the FDA on a pathway to resubmit the RP1 biologics license application in advanced melanoma has refocused attention on Replimune Group’s lead program and helped drive a notable price reaction on its United States home exchange. At the same time, the most recent quarterly figures, including a narrower-than-expected loss per share for Q3 2026, provide additional context on funding and execution as the company prepares for a potential resubmission and its next earnings update. How successfully the group navigates the renewed regulatory process and aligns its clinical spending with investor expectations will remain central themes for market watchers in the coming months.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.